Navigation Links
Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
Date:6/22/2013

CHICAGO, June 22, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from an additional analysis of Phase II clinical data for LY2605541, an investigational novel basal insulin analog. The analysis provides more in-depth information about the reductions in required prandial (mealtime) insulin in LY2605541-treated patients compared to those treated with insulin glargine.[1] These findings are being presented at the 73rd American Diabetes Association Scientific Sessions® in Chicago, June 21–25, 2013.

Initial clinical data from a Phase II study showed that LY2605541-treated patients with type 1 diabetes had greater improvements in glycemic control along with reduced mealtime insulin doses compared to insulin glargine-treated patients.[2] Results from this additional analysis showed that among those who completed the Phase II study, which included eight weeks of treatment with LY2605541 and eight weeks of insulin glargine, LY2605541 led to significantly lower average blood glucose levels (143.1 mg/dL vs. 151.7 mg/dL) with statistically significantly less mealtime insulin per day compared to insulin glargine. The reduced mealtime insulin use was found per day and across all major meals, including:

  • breakfast (-0.9 +/- 0.4 International Units (IU) [13.7 percent reduction]),
  • lunch (-1.4 +/- 0.4 IU [18.6 percent reduction]),
  • dinner (-2.0 +/- 0.4 IU [22.4 percent reduction]), and 
  • total daily dose (-4.3 +/- 1.5 IU) [20.7 percent reduction in units]).[1]

LY2605541-treated patients had a statistically higher overall hypoglycemia rate (blood glucose less than or equal to 70 mg/dL) compared to insulin glargine (9.2 vs. 8.1 events/30 days) but a statistically lower rate
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy
2. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
3. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
4. Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib
5. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
6. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
7. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
8. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
9. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
10. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
11. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 The American Association ... Medical Design and Manufacturing has joined the AAHomecare Corporate ... Harvey Diamond have been actively involved in ... as it has quickly grown into a major global ... like Drive allows AAHomecare to increase efforts on behalf ...
(Date:9/19/2014)... -- According to market research report, ... & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, Surgical Procedure, ... Geography - Global Trends & Forecast to 2019", ... market on the basis of various types, applications, ... market size of each of these segments in ...
(Date:9/19/2014)... and ORLANDO, Fla. , ... supporting Inspire therapy continues to grow, with the publication ... published on-line in Otolaryngology – Head and ... causes a worsening of both objective and subjective measures ... directly attribute Inspire therapy for the reduction in obstructive ...
Breaking Medicine Technology:Drive Medical Design & Manufacturing Joins AAHomecare Corporate Partner Program 2Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4
(Date:9/21/2014)... UNIWIGS, one of the leading online stores ... pieces, offers a line of human hair lace wigs inspired ... also shows people what the latest celebrity hairstyles ... there are 4 different hairstyles to choose from: a style ... lace wigs and a hot ombre red lace wig. People ...
(Date:9/21/2014)... More than a quarter of house fires are ... of two ways. The first type of dryer fire occurs ... type of dryer fire occurs when lint builds up in the ... due to malfunctioning electrical systems so if it doesn’t appear to ... Here are some ways that you can prevent dryer fires. , ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 Expert witness ... released the findings from its 2014 Expert Witness Fees ... increasingly complex, the demand and compensation for qualified and ... in the Survey’s 16-year history. , The nearly ... hour for their expert work, an increase of 3.2% ...
(Date:9/21/2014)... "I wanted to be able to ... sugary, foul-tasting energy drinks," said an inventor from Fresh ... to drink plain, old coffee. That is why I ... developed ENERG CHEWING GUM to provide a healthy energy ... formula contains nutritious vitamins, minerals and antioxidants. It also ...
(Date:9/21/2014)... "I want to help people who are having ... money for chiropractors," said an inventor from St. Amat, ... for myself." , The Stretch is a device that ... and align the spine properly. It improves flexibility and ... nerves. Compact and easy to use, it's ideal for ...
Breaking Medicine News(10 mins):Health News:UniWigs New Arrivals Just In- Human Hair Lace Wigs Inspired By Famous Celebrities 2Health News:Restoration Local Offers Tips to Avoid Dryer Fires 2Health News:Restoration Local Offers Tips to Avoid Dryer Fires 3Health News:ExpertPages 2014 Survey Reports Expert Witness Hourly Fees Record All-Time Highs as Demand for Qualified Experts Continues to Grow 2
... of deadly neuroectodermal tumors , MONDAY, Dec. 7 (HealthDay ... role in a particularly aggressive type of childhood brain ... tumors (CNS-PNETs), the discovery of these oncogenes may lead ... , "Lack of insight into the molecular pathogenesis of ...
... , , SAN FRANCISCO, Dec. 7 Senior advocacy organizations ... grant from Verizon on Tuesday (Dec. 8) to continue the Commitment to End Abuse ... Hank Lacayo, president and CEO, Congress of California Seniors, ... and CEO, Self-Help for the Elderly, ...
... , GREENDALE, Wis., Dec. 7 Taste of Home ... Comfort Food Diet Cookbook, featuring America,s favorite comfort recipes with ... Food Diet Cookbook , on shelves December 31, 2009, is a ... pounds without feeling deprived. Enjoy pizza, lasagna, mac-n-cheese, pulled pork and ...
... ― The second-generation proteasome inhibitor carfilzomib is showing noteworthy ... among multiple myeloma patients in a phase II clinical ... of the American Society of Hematology. The updated ... relapsed or resistant multiple myeloma who have received one ...
... ... dental emergency, finding a qualified, experienced dentist is a crucial step in preserving your smile ... Minneapolis, ... stand against the high prices and inconvenience of emergency dental procedures. Whether a tooth is ...
... fewer hassles, study finds , MONDAY, Dec. 7 (HealthDay News) ... just as effective in preventing dangerous venous clots as an ... to manage, a new study finds. , Dabigatran is marketed ... not yet approved for use in the United States. , ...
Cached Medicine News:Health News:New Target May Be Eyed in Kids' Brain Cancer 2Health News:The Country's Largest Cooking Magazine Announces The Comfort Food Diet Cookbook 2Health News:The Country's Largest Cooking Magazine Announces The Comfort Food Diet Cookbook 3Health News:Drug shows positive responses, low side-effects in multiple myeloma 2Health News:Minneapolis Dentists, Shamblott Family Dentistry, Ease the Pain and Cost of Emergency Dental Procedures 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 3
7mm Cross Hairs; Available in 4.5mm to 7.0mm in 0.5mm increments; Ring depth available from 2 to 4mm in 0.5mm increments.; in stainless steel....
2.0mm Rounded Tip, 12mm From Tip to Bend Gently Curved, 15mm Shaft; In Titanium...
Double ended with 0.5mm x 10mm and 1.0mm x 15mm blades; both blades gently curved; round serrated handle, In Titanium....
0.6mm Tip x10mm Shaft, Straight Shaft, 90 Degree Hook at Tip; overall length 120mm; in Titianium....
Medicine Products: